Senile systemic amyloidosis: clinical features at presentation and outcome.

Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. · 2013

Read Senile systemic amyloidosis: clinical features at presentation and outcome. by Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3647259.txt.

Introduction

A heart disease of old age is charted from first signs to outcome by Pinney and a large team in a 2013 study in the Journal of the American Heart Association. The disease, senile systemic amyloidosis, comes from a blood protein that folds wrong and clogs organs, above all the heart. It must be told apart from a kin heart form tied to blood cell faults, since care differs.

The study covers 102 patients with the age-linked form and 36 with the heart-only blood form, seen at the United Kingdom National Amyloidosis Centre from 2002 to 2011. Median survival from first symptoms ran 6.07 years in the age-linked group against 1.7 years in the other. A blood stress marker, a pacemaker and worse breathlessness marked poorer outlook. Age plus one blood test level helped tell the two forms apart at first visit.

Catalog record

CREATORPinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3647259

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome By Jennifer H. Pinney, Carol J. Whelan, Aviva Petrie, Jason Dungu, Sanjay M. Banypersad, Prayman Sattianayagam, Ashutosh Wechalekar, Simon D. J. Gibbs, Christopher P. Venner, Nancy Wassef, Carolyn A. McCarthy, Janet A. Gilbertson Published in: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease DOI: 10.1161/JAHA.113.000098 ABSTRACT Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types. We report the clinical presentation, natural history, and prognostic features of ATTRwt compared with cardiac‐isolated AL amyloidosis and calculate the probability of disease diagnosis of ATTRwt from baseline factors. Methods and Results All patients with biopsy‐proven ATTRwt (102 cases) and isolated cardiac AL (36 cases) seen from 2002 to 2011 at the UK National Amyloidosis Center were included. Median survival from the onset of symptoms was 6.07 years in the ATTRwt group and 1.7 years in the AL group. Positive troponin, a pacemaker, and increasing New York Heart Association (NYHA) class were associated with worse survival in ATTRwt patients on univariate analysis. All patients with isolated cardiac AL and 24.1% of patients with ATTRwt had evidence of a plasma cell dyscrasia. Older age and lower N‐terminal pro‐B‐type natriuretic peptide (NT pro‐BNP) were factors significantly associated with ATTRwt. Patients aged 70 years and younger with an NT pro‐BNP <183 pmol/L were more likely to have ATTRwt, as were patients older than 70 years with an NT pro‐BNP <1420 pmol/L. Conclusions Factors at baseline associated with a worse outcome in ATTRwt are positive troponin T, a pacemaker, and NYHA class IV symptoms. The age of the patient at diagnosis and NT pro‐BNP level can aid in distinguishing ATTRwt from AL amyloidosis. INTRODUCTION Without effective treatment cardiac amyloidosis is a fatal disease. There are 3 major amyloid types that affect the heart: light‐chain (AL) amyloidosis, hereditary transthyretin amyloidosis (ATTRm), and wild‐type transthyretin amyloidosis (ATTRwt), also known as senile cardiac amyloidosis.1–3 Correctly identifying the amyloid type is vital, as it has a major impact on prognosis and completely dictates treatment. Biopsy followed by Congo Red staining and immunohistochemistry is the gold standard for diagnosing and typing amyloid.4 Correct diagnosis of isolated cardiac amyloidosis clinically is especially challenging as symptoms are often nonspecific. The diagnosis of ATTRm is relatively straightforward if genetic screening of the TTR gene is performed, but differentiating between ATTRwt and AL amyloidosis can be more problematic. ATTRwt invariably affects older patients, who may well have an incidental monoclonal gammopathy of undetermined significance (MGUS). If the coexistence of amyloidosis and a plasma cell dyscrasia alone is used as evidence of AL amyloidosis, chemotherapy‐based treatment may be given in error.5 Recent advances in cardiac magnetic resonance imaging (MRI) have led to a dramatic increase in detection of late gadolinium enhancement, which is reported to be characteristic of amyloidosis. Some features appear more characteristic of ATTR amyloid such as transmural late gadolinium enhancement (LGE) and right ventricular LGE, but currently MRI appearances cannot differentiate between amyloid types.6 ATTRwt amyloidosis is almost certainly underdiagnosed,7 and as the prevalence increases with age and the population demographic shifts toward the elderly, the burden of disease will become an increasing problem.8–9 Currently there is no specific licensed treatment for ATTRwt amyloidosis, but new drugs are on the horizon, with several clinical trials currently recruiting patients with transthyretin amyloidosis (http://clinicaltrials.gov/ct2/results?term=transthyretin). Defining the clinical course of the disease is important both for patient counseling for a disease for which there is currently limited literature and to identify clinical diagnostic and response criteria for further treatment trials.10–11 Here we report the clinical presentation of 102 patients with ATTRwt seen at the UK amyloid referral center between 2002 and August 2011 and compare them to 36 patients with isolated cardiac AL amyloidosis. We describe the natural history of the disease and identify baseline factors that are associated with poor survival. By comparing patients with ATTRwt and isolated cardiac AL amyloidosis, we have created a model to calculate the probability of a diagnosis of ATTRwt amyloidosis. From this model we have designed a diagnostic algorithm that can help to guide a diagnostic approach. METHODS Patients We analyzed all 102 patients with biopsy‐confirmed ATTRwt diagnosed between 2002 and August 2011 at a single UK center and compared them with the 36 patients with biopsy‐confirmed isolated cardiac AL amyloidosis diagnosed over the same period at the same center. Patients were referred from throughout the United Kingdom and Ireland. All referrals were accepted irrespective of the previous investigations or prior evidence of amyloid. In the AL group, 20 patients were referred from cardiology, and 16 patients were referred by hematologists; all AL patients had been seen by a cardiologist before initial assessment at our center. In the ATTRwt group, 73 patients were referred from cardiology, 18 from hematology, 3 from general practice, 2 each from gastroenterology and urology, and 1 each from elderly care, neurology, rheumatology, and respiratory medicine. Ninety‐three of the 102 patients in the ATTRwt group had been seen before referral by a cardiologist. At our center all patients had an initial diagnostic assessment that included clinical evaluation, ECG, echocardiogram, serum amyloid P component (SAP) scintigraphy, and biochemical evaluation. Onset of symptoms was defined on the basis of the history, but a diagnosis of amyloidosis was dated from the biopsy, which provided histological proof of amyloid. If necessary after our initial assessment, advice was given to the referring doctor regarding further investigations required to confirm the diagnosis histologically. Patients were then reviewed at 6 to 12 monthly intervals. Follow‐up assessment comprised clinical and biochemical evaluation, ECG, and echocardiogram. N‐terminal pro‐B‐type natriuretic peptide (NT pro‐BNP) concentration was measured in all patients presenting after 2007. In patients diagnosed earlier, NT pro‐BNP was measured on banked serum samples that had been kept at −30°C. Evidence of a plasma cell dyscrasia was defined as any of the following: detectable M‐protein on plasma electrophoresis or immunofixation, Bence Jones proteins in urine, or abnormal serum free light‐chain level (kappa >19.4, lambda >26.3) or abnormal ratio (0.26 to 1.65). The study was approved by the Ethics Committee of the Royal Free Hospital, and patients provided informed consent. Diagnostic Procedures Amyloid deposition was confirmed histologically in all patients; sections from formalin‐fixed, paraffin‐embedded biopsy specimens were stained with Congo Red and viewed under cross‐polarized light.4 Immunohistochemical staining of amyloid deposits was performed using monospecific antibodies reactive with SAA, kappa, lambda, and transthyretin as previously described.12 A diagnosis of AL amyloidosis was only made if there was positive kappa or lambda immunohistochemical staining of amyloid in endomyocardial tissue. All the ATTRwt patients had immunohistochemical confirmation of transthyretin amyloidosis from a variety of tissues. All patients with transthyretin amyloidosis were confirmed to be wild type on genotyping. Genomic DNA was extracted from whole blood treated with EDTA.13 The coding regions of the transthyretin gene were amplified by polymerase chain reaction assay. Exons 2, 3, and 4 of the TTR gene were sequenced as previously described.14 All patients had amyloidotic cardiomyopathy defined by either endomyocardial biopsy proof of amyloid deposition or a mean left ventricular wall thickness (septum and posterior wall) >12 mm in

Read the complete text